Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05261386 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
A Phase 2 study, sponsored by Cloudbreak Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT05261386 is a Phase 2 study that has completed, run by Cloudbreak Therapeutics. The registered enrollment target is 95 participants.
The verdict
NCT05261386, a Phase 2 study, has completed, sponsored by Cloudbreak Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical ophthalmic solution Control Treatment: CBT-008 vehicle
Interventions
- DRUG CBT-008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05261386
The ClinicalTrials.gov registry entry for NCT05261386 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cloudbreak Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBT-008 is the first listed.
NCT05261386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05261386 about?
NCT05261386 is a clinical study titled "Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction". Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical ophthalmic solution Control Treatment: CBT-008 vehicle
What is the current status of trial NCT05261386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2022-03-04. Estimated completion is 2023-03-29.
What interventions are being tested in trial NCT05261386?
The interventions under investigation include: CBT-008 (DRUG).
Who is sponsoring clinical trial NCT05261386?
This trial is sponsored by Cloudbreak Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.